Honoring Brain Cancer Awareness Month: Advancing Research, Raising Voices, and Recruiting for Clinical Trials
May is Brain Cancer Awareness Month! A time dedicated to elevating the voices of patients, caregivers, and advocates affected by brain tumors. At Plus Therapeutics, we stand in solidarity with the entire brain cancer community and remain committed to advancing new and effective treatments for this devastating disease.
Every day, our dedicated network of scientists, engineers, and physicians across the U.S. works to develop innovative therapies aimed at treating some of the most aggressive brain cancers, including glioblastoma (GBM). Our lead radiotherapeutic candidate, REYOBIQ™ (rhenium-186 Re obisbemeda), is currently in clinical development and offers hope through targeted, localized treatment.
Special thanks to The National Brain Tumor Society (NBTS) for their tireless efforts in bringing visibility and support to this community all year long.
Now Enrolling: ReSPECT-GBM Phase 2 Clinical Trial
We are actively recruiting patients diagnosed with recurrent glioblastoma (GBM) for our ongoing ReSPECT-GBM Phase 2 trial. This clinical study evaluates the safety and efficacy of REYOBIQ™ using convection-enhanced delivery (CED)—a promising approach that delivers therapy directly to the tumor site.
🔍 Learn more or refer someone today:
http://respect-trials.com/gbm
Contact us: respect@plustherapeutics.com
#BrainCancerAwarenessMonth #GrayMay #GoGrayInMay #BrainTumorStrong #BrainCancer #Glioblastoma #GBM #BTAM #REYOBIQ #Radiotherapeutics #RESPECTGBM #ClinicalTrials #Oncology #CancerResearch #PlusTherapeutics #NBTS
Recent Comments